**Anal Cancer - Pipeline Review, H1 2016**

**Description:** Anal Cancer - Pipeline Review, H1 2016

**Summary**


The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

**Note**: Certain sections in the report may be removed or altered based on the availability and relevance of data.

**Scope**

- The report provides a snapshot of the global therapeutic landscape of Anal Cancer
- The report reviews pipeline therapeutics for Anal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Anal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anal Cancer

**Reasons to buy**

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Anal Cancer Overview
Therapeutics Development
Pipeline Products for Anal Cancer - Overview
Pipeline Products for Anal Cancer - Comparative Analysis
Anal Cancer - Therapeutics under Development by Companies
Anal Cancer - Therapeutics under Investigation by Universities/Institutes
Anal Cancer - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Anal Cancer - Products under Development by Companies
Anal Cancer - Products under Investigation by Universities/Institutes
Anal Cancer - Companies Involved in Therapeutics Development
Advaxis, Inc.
Amgen Inc.
Eli Lilly and Company
Genticel S.A.
ISA Pharmaceuticals B.V.
Novartis AG
Oryx GmbH & Co. KG
PDS Biotechnology Corporation
Sun Pharma Advanced Research Company Ltd.
Taiwan Liposome Company, Ltd.
Anal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
axalimogene filolisbac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GTL-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISA-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LN-145 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paclitaxel albumin free - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panitumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress

PDR-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

PDS-0101A - Drug Profile
Product Description
Mechanism of Action
R&D Progress

prexasertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress

TLC-388 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Vicoryx - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Anal Cancer - Recent Pipeline Updates

Anal Cancer - Dormant Projects

Anal Cancer - Product Development Milestones

Featured News & Press Releases

Dec 16, 2015: FDA Lifts Advaxis Clinical Hold On Axalimogene Filolisbac


Nov 02, 2015: Advaxis Provides Additional Information on Clinical Hold

Apr 06, 2015: Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer

Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer
Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience

Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV

Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV

Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy

Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Anal Cancer, H1 2016

Number of Products under Development for Anal Cancer - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Anal Cancer - Pipeline by Advaxis, Inc., H1 2016

Anal Cancer - Pipeline by Amgen Inc., H1 2016

Anal Cancer - Pipeline by Eli Lilly and Company, H1 2016

Anal Cancer - Pipeline by Genticel S.A., H1 2016

Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016

Anal Cancer - Pipeline by Novartis AG, H1 2016

Anal Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016

Anal Cancer - Pipeline by PDS Biotechnology Corporation, H1 2016
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Anal Cancer - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3665237/
Office Code: SCD2I67G

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 6000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:
Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World